IFW

APR 16 2007 \$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BERNARDS et al.

Atty. Ref.:

620-378

Serial No.

10/542,024

Group:

1645

Filed:

July 11, 2005

Examiner:

To be assigned

For:

MODULATION OF DEUBIQUITINASE FAMILY MEMBERS

Commissioner for Patents P.O. Box 1450

April 16, 2007

P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

 \boxtimes 1. PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

\boxtimes	4.	A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.					
This	paper	is submitted in accordance with:					
\boxtimes	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]					
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and					
		a) The required Statement made in item 8 below; or					
		b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.					
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement <u>and</u> Rule 17(p) fee), but before final fee payment]; and					
		 a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and 					
		b) The required Statement is stated in item 8 below.					
	8.	Statement under 37 CFR 1.97(e)					
		a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or					
		b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					

BERNARDS et al. Serial No. 10/542,024

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

R I Sad

Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

PNFORM	IATION DISCLOSU	RE ATTY. DOCKET	NO.	SERIAL NO.				
40	CITATION	620-378		10/542,024	· 			
1 6 2007		APPLICANT						
ָבָּר י ַ	9	BERNARD	S et al.					
(U.86)	everal sheets if necessary)	FILING DATE		GROUP				
PADEM MET		July 11, 20	05	1645				
		U.S. PAT	ENT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPR		
		ļ						
			<u> </u>					
		<u> </u>						
		 						
		FOREIGN	PATENT DOCUMENT	rs	<u> </u>			
						TRANS		
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	N	
	WO 00/31548	06/2000	WIPO					
	WO 02/09761	02/2002	WIPO					
							<u> </u>	
							├-	
							-	
							 	
	OTHER ROCHE	IENTS (in alredia	a Author Title Date	Portinent no	l coo oto	<u> </u>	<u> </u>	
	Furancan Socrah	Penert deted E	ng Author, Title, Date ebruary 14, 2007, issu	, rerunent pa	iges, etc.	<u>)</u> :D 04 7	<u>'</u> ^	
	2705							
	Brummelkamp et al, "Loss of the cylindromatosis tumour suppressor inhibits apoptosis by							
	activating NF- _K B"	, NATURE, Aug	ust 14, 2003, Vol. 424	, pp 797-801				
						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
1 - 1								
Examiner			Date Considered					